

Innovax-ILT-IBD (--)- Concentrate and solvent for suspension for injection

Authorised

- Turkey herpesvirus, strain HVT/IBD/ILT (cell-associated), expressing VP2 protein gene of Infectious bursal disease virus and gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live

Product identification

Medicine name:

Innovax-ILT-IBD (--)- Concentrate and solvent for suspension for injection

Active substance:

Turkey herpesvirus, strain HVT/IBD/ILT (cell-associated), expressing VP2 protein gene of Infectious bursal disease virus and gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live

Target species:

Chicken

Chicken (embryonated eggs)

Route of administration:

In ovo

Subcutaneous use

Product details

Active substance and strength:

Turkey herpesvirus, strain HVT/IBD/ILT (cell-associated), expressing VP2 protein gene of Infectious bursal disease virus and gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live

Presentation_strength:from $10^{3.2}$ to $10^{4.6}$ PFU Index:0

Pharmaceutical form:

Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:

In ovo:

-

Chicken

- Not applicable. 0 day Zero days

-

Chicken (embryonated eggs)

- Not applicable. 0 day Zero days

Subcutaneous use:

-

Chicken

- Not applicable. 0 day Zero days

-

Chicken (embryonated eggs)

- Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Bulgaria , Czechia , France , Germany , Greece , Hungary , Italy , Netherlands , Poland , Portugal , Spain , Sweden

Package description:

Packaging:Concentrate: ampoule (glass), Package_size:Concentrate: 1 ampoule, Content:Concentrate: 2 ml (4000 doses)

Packaging:Concentrate: ampoule (glass), Package_size:Concentrate: 1 ampoule, Content:Concentrate: 2 ml (2000 doses)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Intervet International B.V.

Marketing authorisation date:

14/04/2023

Manufacturing sites for batch release:

Intervet International B.V.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

14/04/2023

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 19/02/2024

[Download](#)

ema-puar-v5905-innovaxiltibd-en.pdf